Pfizer Inc. [NYSE: PFE] price plunged by -0.67 percent to reach at -$0.27. The company report on March 16, 2023 that Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer.
Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial .
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial were randomized to one of three study arms: XTANDI plus leuprolide, placebo plus leuprolide, or XTANDI monotherapy. The study met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated with XTANDI plus leuprolide versus placebo plus leuprolide.
A sum of 57351406 shares traded at recent session while its average daily volume was at 21.80M shares. Pfizer Inc. shares reached a high of $40.79 and dropped to a low of $39.985 until finishing in the latest session at $40.10.
The one-year PFE stock forecast points to a potential upside of 22.41. The average equity rating for PFE stock is currently 2.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $51.68 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on March 06, 2023. The new note on the price target was released on February 07, 2023, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another drop from $55 to $47, while UBS kept a Neutral rating on PFE stock. On January 17, 2023, analysts decreased their price target for PFE shares from 54 to 50.
The Average True Range (ATR) for Pfizer Inc. is set at 0.82, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.26. The Price to Book ratio for the last quarter was 2.35, with the Price to Cash per share for the same quarter was set at 4.02. Price to Free Cash Flow for PFE in the course of the last twelve months was 13.31 with Quick ratio for the last quarter at 1.00.
PFE Stock Performance Analysis:
Pfizer Inc. [PFE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.80. With this latest performance, PFE shares dropped by -7.43% in over the last four-week period, additionally sinking by -12.71% over the last 6 months – not to mention a drop of -24.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 34.72, with the RSI for the last a single of trading hit 38.04, and the three-weeks RSI is set at 34.16 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 43.45, while it was recorded at 40.10 for the last single week of trading, and 47.34 for the last 200 days.
Insight into Pfizer Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +37.43 and a Gross Margin at +61.89. Pfizer Inc.’s Net Margin is presently recorded at +31.26.
Return on Equity for this stock inclined to 36.29, with Return on Assets sitting at 16.57.
Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
PFE Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to -5.45%.
Pfizer Inc. [PFE] Insider Position Details
There are presently around $157,792 million, or 70.50% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 501,636,220, which is approximately 1.631% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 442,868,761 shares of the stock with an approximate value of $17.76 billion in PFE stocks shares; and STATE STREET CORP, currently with $11.39 billion in PFE stock with ownership of nearly -1.203% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of Tuesday and at the time of the Tuesday reporting period, where 1,598 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 160,583,530 shares. Additionally, 1,478 investors decreased positions by around 115,556,593 shares, while 332 investors held positions by with 3,658,820,557 shares. The mentioned changes placed institutional holdings at 3,934,960,680 shares, according to the latest SEC report filing. PFE stock had 315 new institutional investments in for a total of 16,583,962 shares, while 115 institutional investors sold positions of 8,044,832 shares during the same period.